Background {#Sec1}
==========

Pneumonia involving multidrug-resistant (MDR) *Acinetobacter calcoaceticus-Acinetobacter baumannii* (Acb) complex usually occurs in critically ill patients and is associated with unfavorable outcomes \[[@CR1]--[@CR3]\]. For MDR Acb complex resistant to most currently available antibiotics, including β-lactams, fluoroquinolones, and aminoglycosides, there are only a few treatment options, such as tigecycline, sulbactam, and colistin \[[@CR4], [@CR5]\].

Tigecycline is a glycylcycline with in vitro activity against MDR Acb complex \[[@CR6]\]. The comparison analysis from the U.S. Food and Drug Administration showed that tigecycline treatment had a higher mortality rate than other antimicrobials in ventilator associated pneumonia (VAP) \[[@CR7]\]. A recent study also reported a significantly lower cure rate in clinically evaluable patients with VAP treated with tigecycline when compared to imipenem (47.9 % versus 70.1 %) \[[@CR8]\]. However, for pneumonia caused by MDR Acb complex resistant to carbapenems and other classes of antibiotics, off label use of tigecycline was common in clinical practice, and the clinical response rates ranged from 60 to 88 % in prior studies \[[@CR9]--[@CR11]\]. Sulbactam is a β-lactamase inhibitor with antimicrobial activity against *Acinetobacter* species \[[@CR12]\]. It is available alone or in combination with ampicillin, and ampicillin doesn't contribute activity or synergism against *A. baumannii* \[[@CR12]\]. Sulbactam or ampicillin/sulbactam had clinical response rates ranging from 67 to 75 % for pneumonia involving MDR *A. baumannii* (MDRAB) or MDR Acb complex in prior studies \[[@CR13]--[@CR15]\].

In our hospital, tigecycline was not available until August 2007. Before that, sulbactam or ampicillin/sulbactam might be the only treatment option with in vitro activity against MDR Acb complex. Thus, we conducted a retrospective study to compare the efficacy of tigecycline-based with sulbactam (or ampicillin/sulbactam)-based treatment for pneumonia involving MDR Acb complex. With a match in the Acute Physiology and Chronic Health Evaluation (APACHE) II score for both groups, a comparison was made between tigecycline-treated adult patients during the period August 2007 to March 2010 and sulbactam (or ampicillin/sulbactam)-treated adult patients during the period September 2004 to July 2007. The clinical efficacy, outcomes and microbiological eradication were included for analyses.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

Chang Gung Memorial Hospital (CGMH)-Linkou is a university-affiliated medical center providing both primary and tertiary health care in northern Taiwan. This retrospective study has been approved by institutional review boards of CGMH- Linkou (Number: 99-1478B and 100-0294B). The ethics committee granted a waiver for informed consent to be obtained.

Study design, patients and treatments {#Sec4}
-------------------------------------

All hospitalized patients who were ≧ 18 years old and had pneumonia involving MDR Acb complex treated with tigecycline between August 2007 and March 2010, and sulbactam or ampicillin/sulbactam between September 2004 and July 2007, were reviewed. Each tigecycline-treated patient was matched to one sulbactam or ampicillin/sulbactam-treated patient based on identical values of APACHE II score and chart number sequence. Patients were excluded if they did not have a matched control or had a combination therapy with tigecycline and sulbactam (or ampicillin/sulbactam). Patients with initial bacteremia were also excluded since tigecycline treatment for bacteremia was controversial.

Pneumonia was diagnosed if the patient had a radiographic infiltrate that was new or progressive, along with at least two of the following clinical characteristics: new onset of fever (≧ 38 °C) or hypothermia (\< 35.5 °C), leucocytosis (leucocyte count \> 12000 cells/mm^3^) or leucopenia (leucocyte count \< 4000 cells/mm^3^), decline in oxygenation (O2 saturation \< 90 %), and increasing amount of purulent sputum \[[@CR16]\]. Pneumonia involving MDR Acb complex was defined as clinical evidence of pneumonia with sputum or tracheal aspirate cultures positive for MDR Acb complex from 1 week before to 3 days after the first dose of tigecycline or sulbactam or ampicillin/sulbactam. Tracheal aspirate and sputum specimens were sent for bacterial culture only if their Gram's stains showed at least 25 neutrophils and less than 10 epithelial cells per low-power field. Growth was assessed semi-quantitatively. The etiologic pathogen of pneumonia was determined if the tracheal aspirate or sputum culture had an at least moderate growth, i.e., the growth confined up to primary streaking line and \> 5 colonies in secondary streaking zone \[[@CR17]\]. Polymicrobial pneumonia was defined as one or more additional etiologic bacterial species concurrently isolated from the respiratory tract during treatment.

All patients in tigecycline group received tigecycline for at least 7 days, with a 100-mg loading dose followed by 50 mg administered intravenously every 12 h. All patients in sulbactam group received intravenous sulbactam 1 g or ampicillin/sulbactam 3 g (at a ratio 2:1) every 6 or 8 h for at least 7 days. Dose and dosing interval were adjusted according to serum creatinine levels. Combination therapy was defined as simultaneous use of another class of antibiotics for at least 3 days. These antibiotics included carbapenems (meropenem or imipenem), fluoroquinolones (ciprofloxacin or levofloxacin), amikacin, cephalosporins (ceftazidime or cefepime), piperacillin, piperacillin-tazobactam, colistimethate, and aztreonam. Delayed treatment was defined as more than 3 days between the detection of airway MDR Acb complex isolates and the first dose of tigecycline or sulbactam or ampicillin/sulbactam.

Microbiology {#Sec5}
------------

Identification of Acb complex depended upon Gram staining and conventional biochemical tests \[[@CR18]\]. Briefly, the isolates were identified as species of the genus *Acinetobacter* based on the following properties: aerobic, Gram-negative, nonmotile coccobacillary rods with a nonfermentative, catalase-positive and oxidase-negative reaction. *Acinetobacter* species with glucose-oxidizing non-haemolytic characteristics were classified as Acb complex. Antimicrobial susceptibility was determined and interpreted according to the criteria of Clinical and Laboratory Standards Institute by disk diffusion method \[[@CR19]\]. Susceptibility to tigecycline was determined using disk diffusion method with Mueller-Hinton agar (BD Microbiology Systems, Cockeysville, MD) with the resistant breakpoint at ≧ 16 mm and susceptible breakpoint at ≦ 12 mm \[[@CR20]\]. An isolate with full or intermediate resistance to amikacin, gentamicin, cefepime, ceftazidime, aztreonam, piperacillin, piperacillin-tazobactam, ciprofloxacin, imipenem and meropenem was defined as MDR Acb complex \[[@CR21]\].

Cultures were collected from 1 week before the first dose of tigecycline or sulbactam (or ampicillin/sulbactam) to the discharge of patients. Pathogens, sites of growth and susceptibility testing were recorded. Microbial eradication of MDR Acb complex was defined as no growth of Acb complex or susceptibility change from MDR strains to susceptible strains in Acb complex in follow-up respiratory tract cultures before and 7 days after treatment cessation. Relapse was defined as new isolation of MDR Acb complex from the respiratory tract cultures within 2 weeks after initial eradication. Initial bacteremia was defined as bacteremia at the beginning of treatment, which meant at least one positive blood culture 1 week before to 3 days after the first dose of tigecycline or sulbactam or ampicillin/sulbactam. Bacteremia during treatment was defined as at least one positive blood culture 3 days after to the end of treatment.

Demography and comorbidity {#Sec6}
--------------------------

Data on age, sex, surgery, and co-morbid illness were gathered by reviewing in-patient medical records. Co-morbid illness included hepatic dysfunction of a serum total bilirubin level over 2.5 mg/dL or liver cirrhosis, renal insufficiency of a serum creatinine level above 2.0 mg/dL or requirement of dialysis, chronic pulmonary disease, heart disease, diabetes mellitus, immune compromise, and hematological or solid organ malignancy. Immune compromise was defined by at least one of the following: use of prednisone or equivalent over 20 mg per day for at least 2 weeks, organ transplant recipient, human immunodeficiency virus infection or acquired immunodeficiency syndrome, neutropenia (absolute neutrophil count less than 500 cells/mm3), use of immunosuppressive agents, and concurrent hematological malignancy.

Clinical conditions and outcomes {#Sec7}
--------------------------------

Ventilator use, vital signs, and infections other than pneumonia during treatment were recorded. Defervescence was defined as normal body temperature for at least 3 days at the end of treatment. Severity of illness was assessed by a modified APACHE II score, which was recorded within 48 h before or after the first dose of tigecycline or sulbactam or ampicillin/sulbactam. The 30-day mortality was defined as death occurring within 30 days after treatment. The chest radiographs were evaluated by at least two investigators. A series of chest radiographs were evaluated during treatment. Clinical resolution of pneumonia at the end of treatment was defined as (1) decreased pulmonary infiltrate, and (2) survival with stationary findings on chest radiographs and defervescence. Thus, patients with persistent fever or death during treatment would be defined as clinical failure if infiltrates were stationary. Progressing infiltrates were defined as clinical failure.

Statistical methods {#Sec8}
-------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences for Windows (Version 15.0; SPSS Inc., Chicago, IL, USA). Categorical variables were compared using χ^2^ test or Fisher exact test, as appropriate. Continuous variables were tested for normality of distributions by Kolmogorov--Smirnov test, and then compared by Student's *t-*test or the Mann-Whitney *U* test, as appropriate. Odds ratios (ORs) and 95 % confidence interval (CI) were calculated. The survival curve was plotted by means of the Kaplan-Meier method, and the log rank test was used to compare univariate survival distribution between tigecycline and sulbactam groups. Variables with a *P* value \< 0.1 in univariate analysis and tigecycline use were included in a logistic regression model for multivariate analysis. All tests were two-tailed, and a *P* value of \< 0.05 was considered significant.

Results {#Sec9}
=======

Patients, demography and concomitant diseases {#Sec10}
---------------------------------------------

One hundred and sixteen tigecycline-treated episodes of pneumonia involving MDR Acb complex were identified in 112 patients, while 177 sulbactam or ampicllin/sulbactam-treated episodes were identified in 173 patients. Finally, 84 tigecycline-treated patients were enrolled and matched to 84 patients treated with sulbactam (26 patients) or ampicillin/sulbactam (58 patients). The mean APACHE II score was 20.1 for both groups. In tigecycline group, 59 (70.2 %) and 25 (29.8 %) patients had positive MDR Acb complex cultures from tracheal aspirates and sputum, respectively. In sulbactam group, 73 (86.9 %) and 11 (13.1 %) patients had that from tracheal aspirates and sputum, respectively. There was no significant difference in age, gender, and concomitant diseases between the two groups (Table [1](#Tab1){ref-type="table"}).Table 1The comparison analysis of demography, concomitant diseases, clinical features, and outcomes between tigecycline (TG) and sulbactam (SB) groupsVariablesTG group^a^SB group^a^*p*OR (95 % CI)*n* = 84*n* = 84Demographic parameters Age, yr69.6 (15.9)70.6 (15.6)0.689 Male gender57 (67.9)58 (69.0)0.8680.946 (0.494--1.814)Concomitant diseases Hepatic dysfunction12 (14.3)6 (7.1)0.1342.167 (0.773--6.075) Renal insufficiency32 (38.1)32 (38.1)1.0001.000 (0.536--1.864) Chronic pulmonary disease22 (26.2)20 (23.8)0.7221.135 (0.564--2.284) Heart disease13 (15.5)7 (8.3)0.1532.014 (0.761--5.333) Diabetes mellitus26 (31.0)35 (41.7)0.1490.628 (0.333--1.183) Immune compromise13 (15.5)11 (13.1)0.6591.215 (0.511--2.891) Malignancy15 (17.9)20 (23.8)0.3420.696 (0.328--1.474)Surgery22 (26.2)15 (17.9)0.1931.632 (0.778--3.423)Clinical conditions APACHE II Score20.1 (6.1)20.1 (6.1)1.000 Ventilator use58 (69.0)75 (89.3)0.0010.268 (0.117--0.615) Pneumonia involving bilateral lung51 (60.7)67 (79.8)0.0070.392 (0.197--0.781) Polymicrobial pneumonia, overall66 (78.6)62 (73.8)0.4691.301 (0.638--2.654) Polymicrobial pneumonia, coinfection with  MRSA26 (31.0)34 (40.5)0.1980.659 (0.349--1.245)   *Pseudomonas aeruginosa*33 (39.3)23 (27.4)0.1021.716 (0.896--3.285)   *Klebsiella* spp*.* ^b^12 (14.3)5 (6.0)0.0732.633 (0.884--7.840)   *Escherichia coli*2 (2.4)2 (2.4)1.0001.000 (0.138--7.270)   *Enterobacter* spp*.* ^c^2 (2.4)2 (2.4)1.0001.000 (0.138--7.270)   *Serratia marcescens*10 (11.9)1 (1.2)0.00511.216 (1.402--89.724)   *Stenotrophomonas maltophilia*6 (7.1)15 (17.9)0.0360.354 (0.130--0.962) Multisite infections, overall33 (39.3)35 (41.7)0.7530.906 (0.489--1.678)  With urinary tract infection13 (15.5)19 (22.6)0.2380.626 (0.287--1.369)  With catheter related infection2 (2.4)10 (11.9)0.0170.180 (0.038--0.851)  With soft tissue and wound infection10 (11.9)5 (6.0)0.1762.135 (0.697--6.540)  With intra-abdominal infection8 (9.5)4 (4.8)0.2312.105 (0.609--7.279)  With invasive fungal infection^d^12 (14.3)4 (4.8)0.0353.333 (1.029--10.799) Bacteremia during treatment4 (4.8)0 (0.0)0.1219.447 (0.501--178.291) With TG or SB-resistant MDR Acb complex^e^16 (19.0)43 (51.2)\< 0.00010.224 (0.112--0.448)Treatment Duration, days14.6 (5.4)16.4 (7.6)0.150 Combination therapy, overall45 (53.6)71 (84.5)\< 0.00010.211 (0.102--0.439)  With cephalosporins20 (23.8)8 (9.5)0.0132.969 (1.226--7.192)  With colistin12 (14.3)0 (0.0)\< 0.000129.138 (1.695--500.773)  With carbapenems5 (6.0)60 (71.4)\< 0.00010.025 (0.009--0.070)  With aminoglycosides7 (8.3)1 (1.2)0.0647.545 (0.907--62.744)  With fluoroquinolones12 (14.3)4 (4.8)0.0353.333 (1.029--10.799) Delayed treatment35 (41.7)22 (26.2)0.0342.013 (1.049--3.863)Outcomes Airway eradication of MDR Acb complex without relapse^f^26 (33.3)47 (63.5)\< 0.00010.287 (0.147--0.560) Defervescence54 (64.3)76 (90.5)\< 0.00010.189 (0.081--0.445) Image study of lung  Improvement37 (44.0)39 (46.4)0.7570.908 (0.495--1.668)  Stationary32 (38.1)22 (26.2)0.0991.734 (0.900--3.342)  Deterioration15 (17.9)23 (27.4)0.1400.577 (0.276--1.204) Clinical resolution of pneumonia56 (66.7)56 (66.7)1.0001.000 (0.526--1.899) Mortality during treatment21 (25.0)15 (17.9)0.2591.533 (0.728--3.231) 30-day mortality28 (33.3)25 (29.8)0.6181.180 (0.615--2.264)*Abbreviations*: *TG* tigecycline, *SB* sulbactam, *OR* odd ratio, *CI* confidence interval, *APACHE* acute physiology and chronic health evaluation, *MRSA* methicillin resistant *Staphylococcus aureus*, *MDR Acb* multidrug resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii*, *ESBL* extended-spectrum beta-lactamase^a^Categorical data are no. (%) of subject, continuous data are expressed as mean (standard deviation)^b^16 patients had coinfection with *Klebsiella pneumoniae*, including 10 with ESBL strains, and 1 had *Klebsiella oxytoca*-ESBL^c^3 patients had coinfection with *Enterobacter cloacae*, and 1 had *Enterobacter aerogenes*^d^15 patients had candidemia, and 1 had possible invasive aspergillosis diagnosed with positive serum galactomannan^e^With TG-resistant MDR Acb complex during TG treatment in TG group, or with SB-resistant MDR Acb commplex during SB treatment in SB group^f^78 patients in TG group and 74 in SB group had available data for evaluation

Clinical conditions {#Sec11}
-------------------

Patients in sulbactam group had more ventilator use (89.3 % versus 69.0 %) and bilateral pneumonia (79.8 % versus 60.7 %) than those in tigecycline group. There were no significant differences between these two groups in the overall rates of polymicrobial pneumonia and multisite infections. *Pseudomonas aeruginosa* and *Methicillin-resistant Staphylococcus aureus* were the most common concurrent pathogens for pneumonia, and urinary tract infection was the most common concurrent infection. However, more patients had *Serratia marcescnes* coinfection and invasive fungal infection in tigecycline group, and more patients had *Stenotrophomonas maltophilia* coinfection and catheter related infection in sulbactam group. Among the 168 enrolled patients, bacteremia during treatment was observed in four patients, and all of them were from tigecycline group (*P* = 0.121). During treatment, tigecycline-resistant MDR Acb complex was isolated in 16 (19.0 %) tigecycline-treated patients, and sulbactam-resistant MDR Acb complex was isolated in 43 (51.2 %) sulbactam or ampicllin/sulbactam-treated patients (19.0 % versus 51.2 %, *P* \< 0.0001) (Table [1](#Tab1){ref-type="table"}). In tigecycline group, 71 patients (84.5 %) had airway MDR Acb complex isolates with full or intermediate resistance to sulbactam. Tigecycline susceptibility testing was not performed in sulbactam group.

Treatment {#Sec12}
---------

The mean treatment duration was 14.6 and 16.4 days for tigecycline and sulbactam group, respectively. Compared to the tigecycline group, more patients in sulbactam group had combination therapy (84.5 % versus 53.6 %), particularly with carbapenems (71.4 % versus 6.0 %). In sulbactam group, the most common co-administered agent were carbapenems (60/71, 84.5 %), followed by cephalosporins (8/71, 11.3 %), and 32 patients (38.1 %) had glycopeptides use. In tigecycline group, the most common co-administered agent was cephalosporins (20/45, 44.4 %), followed by colistin (12/45, 26.7 %) and fluoroquinolones (12/45, 26.7 %). Colistin was not available until May 2007 in our hospital, and co-use of colistin was only noted in tigecycline group. More patients in tigecycline group had delayed treatment (41.7 % versus 26.2 %) (Table [1](#Tab1){ref-type="table"}).

Outcomes {#Sec13}
--------

Sulbactam group had a higher rate of airway MDR Acb complex eradication (63.5 % versus 33.3 %) and defervescence (90.5 % versus 64.3 %) than tigecycline group at the end of treatment. There was no significant difference between these two groups in the rates of clinical resolution, 30-day mortality and mortality during treatment (66.7 % versus 66.7 %; 33.3 % versus 29.8 %; 25.0 % versus 17.9 %, respectively) (Table [1](#Tab1){ref-type="table"}). The cumulative survival rate at 30 days was similar between the two groups by Kaplan-Meier method (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comparative survival curves for tigecycline (*black line*) and sulbactam (*gray line*) groups; Log-rank test: *p* = 0.605. *Abbreviations*: *SB* sulbactam, *TG* tigecycline

The predictor for mortality during treatment {#Sec14}
--------------------------------------------

In the univariate analysis, the survivors were more likely to have tigecycline or sulbactam-resistant MDR Acb complex than the deceased (39.4 % versus 19.4 %) (Table [2](#Tab2){ref-type="table"}). And most of the resistant isolates in survivors were from sulbactam group (39/52, 75 %). In the multivariate analysis including tigecycline-based treatment and variables with a *P* value \< 0.1 in the univariate analysis, bilateral pneumonia was the only independent predictor for mortality during treatment (adjusted OR, 2.717; 95 % CI, 1.015 to 7.272) (Table [2](#Tab2){ref-type="table"}). Other models of multivariate analysis including polymicrobial pneumonia, combination therapy, and combination with carbapenem or colistin also showed that bilateral pneumonia was the only independent predictor (Table [3](#Tab3){ref-type="table"}).Table 2Univariate and multivariate analyses of the predictors for mortality during treatment of tigecycline or sulbactam or ampicillin/sulbactam for pneumonia involving multidrug resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii* (MDR Acb) complexVariablesDeceased^a^Survivors^a^UnivariateMultivariate^b^*n* = 36*n* = 132*pp*Adjusted OR (95 % CI)Demographic parameters Age, yr69.8 (14.7)70.2 (16.0)0.658 Male gender26 (72.2)89 (67.4)0.583Concomitant diseases Hepatic dysfunction6 (16.7)12 (9.1)0.224 Renal insufficiency15 (41.7)49 (37.1)0.619 Chronic pulmonary disease6 (16.7)36 (27.3)0.193 Heart disease6 (16.7)14 (10.6)0.383 Diabetes mellitus14 (38.9)47 (35.6)0.717 Immune compromise5 (13.9)19 (14.4)0.939 Malignancy11 (30.6)24 (18.2)0.105Surgery11 (30.6)26 (19.7)0.163Clinical conditions APACHE II Score20.3 (7.3)20.1 (5.8)0.858 Ventilator use26 (72.2)107 (81.1)0.247 Bilateral pneumonia30 (83.3)88 (66.7)0.0530.0472.717 (1.015--7.272) Polymicrobial pneumonia29 (80.6)99 (75.0)0.488  With MRSA10 (27.8)50 (37.9)0.262  With *Pseudomonas aeruginosa*14 (38.9)42 (31.8)0.425  With *Klebsiella* spp.6 (16.7)11 (8.3)0.207  With *Serratia marcescens*3 (8.3)8 (6.1)0.704  With *Stenotrophomanas maltophilia*6 (16.7)15 (11.4)0.400 Multisite infections18 (50.0)50 (37.9)0.189  With urinary tract infection8 (22.2)24 (18.2)0.584  With catheter related infection2 (5.6)10 (7.6)1.000  With skin and soft tissue infection6 (16.7)9 (6.8)0.0940.2142.070 (0.657--6.521)  With intra-abdominal infection3 (8.3)9 (6.8)0.721  With invasive fungal infection3 (8.3)13 (9.8)1.000Microbiology MDR Acb complex with TG or SB resistance^c^7 (19.4)52 (39.4)0.0260.0790.426 (0.164--1.103) Airway eradication of MDR Acb complex^d^11 (42.3)62 (49.2)0.521 Bacteremia during treatment2 (5.6)2 (1.5)0.201Treatment Tigecycline-based treatment21 (58.3)63 (47.7)0.2590.4511.371 (0.604--3.116) Duration, days15.6 (7.9)15.5 (6.2)0.519 Combination therapy25 (69.4)91 (68.9)0.954  With cephalosporins6 (16.7)22 (16.7)1.000  With carbapenems12 (33.3)53 (40.2)0.457  With fluoroquinolones2 (5.6)14 (10.6)0.527  With colistin3 (8.3)9 (6.8)0.721 Delayed treatment9 (25.0)48 (36.4)0.202*Abbreviations*: *MDR Acb* multidrug resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii*, *OR* odd ratio, *CI* confidence interval, *APACHE* acute physiology and chronic health evaluation, *MRSA* methicillin resistant *Staphylococcus aureus*, *TG* tigecycline, *SB* sulbactam^a^Categorical data are no. (%) of subject, continuous data are expressed as mean (standard deviation)^b^All variables included in the final multivariable model are shown^c^ The initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group^d^26 patients in the deceased group and 126 in the survivors group had available data for evaluationTable 3Multivariate analyses of the predictors for mortality during treatment including combination therapy, carbapenems or colistin use, and polymicrobial pneumoniaVariablesOdds ratio95 % confidence interval*p*Model A^a^ With skin and soft tissue infection2.0410.644--6.4660.225 MDR Acb complex with TG or SB resistance0.4180.160--1.0920.075 Bilateral pneumonia2.6630.987--7.1860.053 Tigecycline-based treatment1.4050.608--3.2450.426 Combination therapy1.1330.472--2.7200.779Model B^b^ With skin and soft tissue infection2.0710.657--6.5230.214 MDR Acb complex with TG or SB resistance0.4260.163--1.1140.082 Bilateral pneumonia2.7171.007--7.3290.048 Tigecycline-based treatment1.3730.497--3.7950.541 Combination with carbapenem1.0020.346--2.9050.997Model C^c^ With skin and soft tissue infection2.0020.624--6.4250.243 MDR Acb complex with TG or SB resistance0.4200.161--1.0900.075 Bilateral pneumonia2.7951.028--7.6000.044 Tigecycline-based treatment1.4300.608--3.3630.413 Combination with colistin0.7830.178--3.4440.746Model D With skin and soft tissue infection2.0350.639--6.4850.230 MDR Acb complex with TG or SB resistance0.4280.165--1.1110.081 Bilateral pneumonia2.7111.013--7.2540.047 Tigecycline-based treatment1.3620.598--3.1020.462 Polymicrobial pneumonia1.1090.426--2.8840.833Model E With skin and soft tissue infection1.9790.612--6.4050.254 MDR Acb complex with TG or SB resistance0.4220.160--1.1100.080 Bilateral pneumonia2.7811.014--7.6240.047 Tigecycline-based treatment1.4220.498--4.0560.510 Polymicrobial pneumonia1.0860.413--2.8530.868 Combination with colistin0.7970.179--3.5570.767 Combination with carbapenem1.0060.346--2.9210.991*Abbreviations*: *MDR Acb* multidrug resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii*, *TG* tigecycline, *SB* sulbactam^a^No significant predictor was revealed when model A included polymicrobial pneumonia^b^Bilateral pneumonia was the only significant predictor when model B included polymicrobial pneumonia (*p* = 0.049, adjusted odds ratio, 2.709; 95 % confidential interval, 1.004--7.305)^c^Bilateral pneumonia was the only significant predictor when model C included polymicrobial pneumonia (*p* = 0.045, adjusted odds ratio, 2.783; 95 % confidential interval, 1.023--7.569)

Monotherapy of tigecycline and sulbactam {#Sec15}
----------------------------------------

Thirty-nine (46.4 %) patients had tigecycline monotherapy and 13 (15.5 %) had sulbactam or ampicillin/sulbactam monotherapy. Tigecycline group had significant lower rates of ventilator use, bilateral pneumonia, and airway eradication of MDR Acb complex. Both groups had similar clinical resolution rates. However, tigecycline group had lower rates of 30-day mortality and mortality during treatment (25.6 % versus 53.8 %, 17.9 % versus 30.8 %, *P* \>0.05). In the univariate analysis for the patients with monotherapy, both the survivors and the deceased during treatment had no significant difference in demography, concomitant diseases, clinical conditions, and treatment (Table [4](#Tab4){ref-type="table"}).Table 4The comparison and outcome analyses of the patients with monotherapy of tigecycline or sulbactamVariablesTG group^a^SB group^a^*p*Deceased^ab^Survivors^a^*pn* = 39*n* = 13*n* = 11*n* = 41Demographic parameters Age, yr71.4 (15.0)68.7 (19.9)0.89975.3 (12.0)69.5 (17.1)0.439 Male gender25 (64.1)10 (76.9)0.5068 (72.7)27 (65.9)1.000Concomitant diseases Hepatic dysfunction3 (7.7)0 (0.0)0.5641 (9.1)2 (4.9)0.518 Renal insufficiency10 (25.6)4 (30.8)0.7291 (9.1)13 (31.7)0.251 Chronic pulmonary disease11 (28.2)4 (30.8)1.0004 (36.4)11 (26.8)0.709 Heart disease6 (15.4)1 (7.7)0.6642 (18.2)5 (12.2)0.630 Diabetes mellitus9 (23.1)4 (30.8)0.7143 (27.3)10 (24.4)1.000 Immune compromise8 (20.5)1 (7.7)0.4202 (18.2)7 (17.1)1.000 Malignancy8 (20.5)3 (23.1)1.0004 (36.4)7 (17.1)0.216Surgery9 (23.1)1 (7.7)0.4192 (18.2)8 (19.5)1.000Clinical conditions APACHE II Score17.0 (6.1)18.2 (6.0)0.55717.1 (6.8)17.3 (5.9)0.904 Ventilator use21 (53.8)11 (84.6)0.0486 (54.5)26 (63.4)0.730 Bilateral pneumonia18 (46.2)12 (92.3)0.0048 (72.7)22 (53.7)0.319 Polymicrobial pneumonia31 (79.5)9 (69.2)0.4669 (81.8)31 (75.6)1.000  With MRSA20 (51.3)6 (46.2)0.7495 (45.5)21 (51.2)0.734  With *Pseudomonas aeruginosa*14 (35.9)3 (23.1)0.5065 (45.5)12 (29.3)0.470  With *Klebsiella* spp.7 (17.9)1 (7.7)0.6621 (9.1)7 (17.1)1.000  With *Serratia marcescens*5 (12.8)1 (7.7)1.0001 (9.1)5 (12.2)1.000  With *Stenotrophomanas maltophilia*3 (7.7)3 (23.1)0.1571 (9.1)5 (12.2)1.000 Multisite infections14 (35.9)5 (38.5)1.0004 (36.4)15 (36.6)1.000  With urinary tract infection7 (17.9)3 (23.1)0.6972 (18.2)8 (19.5)1.000  With catheter related infection0 (0.0)2 (15.4)0.0591 (9.1)1 (2.4)0.382  With skin and soft tissue infection3 (7.7)1 (7.7)1.0001 (9.1)3 (7.3)1.000  With intra-abdominal infection4 (10.3)0 (0.0)0.5610 (0.0)4 (9.8)0.567  With invasive fungal infection6 (15.4)0 (0.0)0.3171 (9.1)5 (12.2)1.000Microbiology MDR Acb complex with TG or SB resistance^c^6 (15.4)4 (30.8)0.2441 (9.1)9 (22.0)0.668 Airway eradication of MDR Acb complex^d^12 (34.3)8 (88.9)0.0064 (57.1)16 (43.2)0.684 Bacteremia during treatment2 (5.1)0 (0.0)1.0001 (9.1)1 (2.4)0.382Treatment Tigecycline-based treatment7 (63.6)32 (78.0)0.435 Duration, days13.8 (5.1)12.7 (5.6)0.29311.9 (3.0)14.0 (5.6)0.398 Delayed treatment20 (51.3)5 (38.5)0.4235 (45.5)20 (48.8)0.845Outcomes Clinical resolution of pneumonia26 (66.7)8 (61.5)0.747 Mortality during treatment7 (17.9)4 (30.8)0.435 30-day mortality10 (25.6)7 (53.8)0.089*Abbreviations*: *TG* tigecycline, *SB* sulbactam, *APACHE* acute physiology and chronic health evaluation, *MRSA* methicillin resistant *Staphylococcus aureus*, *MDR Acb* multidrug resistant *Acinetobacter calcoaceticus-Acinetobacter baumannii*^a^Categorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)^b^Mortality during treatment^c^The initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group^d^35 patients in TG group and 9 in SB group; 7 patients in the deceased group and 37 in the survivors group had available data for evaluation

Discussion {#Sec16}
==========

Prior case series studies reported clinical response rates ranging from 60 to 88 % in tigecycline treatment \[[@CR9]--[@CR11]\], and 67 to 75 % in sulbactam or ampicillin/sulbactam treatment for pneumonia involving MDRAB or MDR Acb complex \[[@CR13]--[@CR15]\]. There were only a few comparative studies investigating the efficacy of tigecycline or sulbactam, and usually they were compared with colistin or polymyxin, the other major treatment option for MDR Acb complex. Betrosian AP et al. reported that high-dose ampicillin/sulbactam monotherapy and colistin were comparably safe and effective treatment for critically ill patients with MDRAB VAP. The clinical success and improvement rate was 76.9 % for ampcillin/sulbactam group and 73.3 % for colistin group \[[@CR22]\]. Oliveira MS et al. reported another study comparing ampicillin/sulbactam with polymyxins in treating infections caused by carbapenem-resistant *Acinetobacter* spp. \[[@CR23]\]. In the study, about half of the enrolled patients had *Acinetobacter* bacteremia, and quarter of them had pneumonia. The mortality rate during treatment was 33 % in ampicillin/sulbactam group and 50 % in polymyxin group, and polymyxin use was an independent factor associated with mortality during treatment \[[@CR23]\]. Chuang YC et al. reported a study comparing tigecycline-based to colistin-based therapy for MDRAB pneumonia in intensive care units. The tigecycline group has an excess mortality of 16.7 % (60.7 % versus 44 %, *P* = 0.04). The excess mortality of tigecycline is significant only among those with minimal inhibitory concentration (MIC) \> 2 μg/mL, but not for those with MIC ≦ 2 μg/mL \[[@CR24]\].

To our knowledge, the study was the first comparative study of tigecycline-based versus sulbactam or ampicillin/sulbactam-based treatment for pneumonia involving MDR Acb complex. Our two patient groups were from different but successive time periods, and the major treatment for MDR Acb complex was different in each time period in our hospital. Before August 2007, sulbactam or ampicillin/sulbactam was the only option probably with in vitro activity against MDR Acb complex in our hospital. After that, tigecycline became the major treatment option because of its high susceptibility rate to MDR Acb complex. However, the clinical and microbiological diagnostic criteria and definition, and standards of care and infection control were similar in both time periods. Covariate adjustment with multivariate analyses and matching with disease severity were performed to reduce bias of the historically controlled comparison.

The patients from both groups were aged with complicated underlying diseases and high disease severity. Higher rates of ventilator use and bilateral pneumonia reflected that sulbactam group might have a higher severity of pneumonia than tigecycline group. A higher rate of delay use in tigecycline group might reflect the early policy of tigecycline use in our hospital: usually tigecycline was not used as empiric or first-line regimen for nosocomial infection. Both groups had similar clinical outcomes. Bilateral pneumonia was the only independent predictor for mortality during treatment in different models of multivariate analysis. Combination therapy did not stand out as an independent predictor, which might be due to difference of combination strategies and regimens between the two patient groups. Most patients in sulbactam group had combination with carbapenem for synergistic effect against MDR Acb complex; however, tigecycline group mainly had anti-pseudomonal cephalosporins and fluoquinolones to cover *Pseudomonas aeruginosa*.

Because most patients in sulbactam group had concurrent carbapenem use, the study results in them might mainly reflect the efficacy of combination of sulbactam and carbapenem. In the comparative analyses of monotherapy, the patients with sulbactam or ampicillin/sulbactam monotherapy had relatively higher mortality rates than the patients with tigecycline monotherapy or the overall sulbactam group. The results implied that combination with carbapenem might improve clinical outcomes of sulbactam-based treatment. Besides, more than half of the sulbactam group had sulbactam-resistant MDR Acb complex isolates during treatment. Combination with carbapenem might play a role giving a high airway eradication rate. The patients with sulbactam monotherapy also had a high airway eradication rate, but most of them did not have sulbactam-resistant MDR Acb complex.

Synergistic effect against MDRAB with the combination of sulbactam and carbapenem had been reported \[[@CR4], [@CR25]\]. However, the synergistic effect was associated with the MICs of carbapenem and sulbactam. If the MICs exceeded achievable serum levels, the potential of sulbactam/carbapenem combination as treatment regimen for MDRAB infections might be limited \[[@CR4]\]. In our study, full or intermediate sulbactam resistance was detected in 84.5 % of tigecycline-treated patients, therefore, physicians tended to use tigecycline for these patients with sulbactam-resistant MDB Acb complex. For these cases, the clinical outcomes of sulbactam group might not be achieved if they received sulbactam/carbapenem combination therapy.

There are some other limitations in this study. First, our respiratory specimens were clinical specimens from clinical practice, and they might not be obtained from deep sites in the lungs. Growths of etiologic pathogens were assessed semi-quantitatively if the specimens were qualified for culture. We cannot absolutely distinguish airway MDR Acb complex infections from colonization. However, our definition for pneumonia was practical, and our conclusion based on clinically relevant data and management could provide important information for clinical practice. Second, polymicrobial pneumonia and concomitant infections were common, and the clinical impact of other etiologic pathogens or extrapulmonary infections was not evaluated comprehensively. Third, we studied MDR Acb complex rather than MDRAB. Although prior studies reported that about 90 % of Acb complex with multidrug or carbapenem resistance was the genomic specie of *A.baumannii*, comparison with studies on *A. baumannii* isolates are not straightforward \[[@CR26]\].

Conclusions {#Sec17}
===========

Tigecycline-based treatment had a similar clinical outcome to sulbactam or ampicillin/sulbactam-based treatment for pneumonia involving MDR Acb commplex, but tigecycline group had a lower microbiological eradiation rate. More comparison studies are essential to establish the optimal regimens for pneumonia involving MDR Acb complex.
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